Stock Analiz

Bicycle Therapeutics PLC BCYC

Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026

$3.37Market cap $236M
Open the interactive analysis →

Bicycle Therapeutics PLC (BCYC) is a healthcare company listed in the US with a market value of about $236M. In the twelve months to September 30, 2026 it had revenue of $84M and net income of -$142M, a net margin of -169.8%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 48% a year, a 5-year average ROIC of -29%.

About Bicycle Therapeutics

Bicycle Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2019. Revenue went from $2M in 2017 to $73M in 2025, growth of about 56.1% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 134% over three years (dilution for shareholders). It spends 331% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2.8
P/B0.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-75.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)105.8%
Revenue growth (5 yrs, per year)47.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-560.2%
ROIC (5-yr avg.)-29.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$84M$73M$35M$27M$14M$12M$10M$14M$7M$2M
Net income-$142M-$219M-$169M-$181M-$113M-$67M-$51M-$31M-$22M-$16M
Free cash flow-$177M-$252M-$166M-$64M-$105M-$17M-$19M-$30M-$27M-$3M
EPS (diluted)$-2.03$-3.16$-2.90$-5.08$-3.80$-2.67$-2.66$-2.77$-49.78$-48.81
Net margin-169.8%-301.7%-479.2%-669.7%-779.4%-571.2%-491.0%-221.8%-306.1%-789.3%
ROIC—-31.1%-25.4%-36.1%-36.5%-16.4%-46.1%-27.4%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 6 analysts is $9.17, 172% above the current price; targets range from $5.00 to $14.00; the consensus rating is “Buy”; expected EPS is $-2.26 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Bicycle Therapeutics pay a dividend?

Not currently.

Is Bicycle Therapeutics a good stock to buy?

We do not give buy or sell advice. Bicycle Therapeutics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.